U.S. FDA Approves VIZIMPRO® (dacomitinib) 롱

Pfizer, Inc.NYSE

설명

⋅ 2018년 9월 28일 오후 4시 33분

PFE: Pfizer Inc.
2018-09-27 17:41:00
U.S. FDA Approves VIZIMPRO® (dacomitinib) for the First-Line Treatment of Patients with EGFR-Mutated Metastatic Non-Small Cell Lung Cancer

Beyond Technical Analysis

코멘트

ForExtraPips

⋅ 2018년 9월 30일 오후 6시 40분

Good to hear. I bought a call @ 43.00 on the 17th of Sep. Targeting between 52.00 and 55.00 by the end of this year.